Closed · PA-09-238 · CFDA 93.393;93.394 · Discretionary
Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $200K
- Award range
- Closed
- Status
- September 7, 2012
- Close date
- -
- Expected awards
The verdict
Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21) is a closed discretionary listing from National Institutes of Health that offered Up to $200,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $200K
- award range
- Closed
- application status
- 93.393;93.394
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Exfoliated Cells and Circulating DNA in Cance… is closed (last close September 7, 2012). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed September 7, 2012
Instrument
Grant
Description
Purpose.This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications aimed at the development of novel technologies for capturing, enriching, and preserving exfoliated abnormal cells from body fluids or effusions as well as methods for concentrating the tumor-derived sub-cellular material for use in biomarker studies. In body fluids, such as sputum, exfoliated tumor cells are a minor component compared to normal cells. As a result, the detection of exfoliated abnormal cells by routine cytopathology is often limited by the low number of atypical cells present in a given specimen. New enrichment methods are necessary to facilitate the detection of very low levels of exfoliated tumor cells and tumor-derived sub-cellular materials in biological fluids. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.
Market-open applicant set · includes for-profit door
The eligibility set for Exfoliated Cells and Circulating DNA in Cance… includes a for-profit door among 6 printed types (Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Nonprofits without 501(c)(3) status (other than IHEs); Private institutions of higher education; +2 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). Only 6 other National Institutes of Health listings share this exact eligibility-code string (0% of 12,420).
- Code 06
- Public / state-controlled institutions of higher education
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Exfoliated Cells and Circulating DNA in Cance… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.393;93.394 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |